Femasys (FEMY) said Monday it has received 510(k) clearance from the US Food and Drug Administration for FemChec, a tool designed for controlled delivery of contrast to check the status of fallopian tubes.
It is part of the company's non-surgical permanent birth control method, dubbed FemBloc, Femasys said.
The company added that it will continue to work with the regulator as FemBloc moves through a late-stage trial that is currently enrolling.
Price: 1.07, Change: -0.01, Percent Change: -0.47
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。